BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wombwell E, Patterson ME, Bransteitter B, Gillen LR. The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection. Clinical Infectious Diseases 2020. [DOI: 10.1093/cid/ciaa808] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Maziade PJ, Ship N, Sniffen JC, Goldstein EJC. Enhanced Clostridioides difficile infection prevention with a pharmacy-controlled policy that adds a three-strain Lactobacillus probiotic concomitantly to antibiotic therapy. Clin Infect Dis 2021:ciab414. [PMID: 33966076 DOI: 10.1093/cid/ciab414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Reigadas E, van Prehn J, Falcone M, Fitzpatrick F, Vehreschild MJGT, Kuijper EJ, Bouza E; European Society of Clinical Microbiology and Infectious Diseases Study Group on Clostridioides difficile (ESGCD) and Study Group for Host and Microbiota interaction (ESGHAMI). How to: prophylactic interventions for prevention of Clostridioides difficile infection. Clin Microbiol Infect 2021:S1198-743X(21)00368-2. [PMID: 34245901 DOI: 10.1016/j.cmi.2021.06.037] [Reference Citation Analysis]
3 McFarland LV, Johnson SB, Evans CT. Perils and pitfalls of probiotic quasi-experimental studies for primary prevention of Clostridioides difficile infection: A review of the evidence. Am J Infect Control 2021;49:375-84. [PMID: 32791261 DOI: 10.1016/j.ajic.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Choi MH, Kim D, Jeong SH, Lee HM, Kim H. Risk Factors of Severe Clostridioides difficile Infection; Sequential Organ Failure Assessment Score, Antibiotics, and Ribotypes. Front Microbiol 2022;13:900681. [DOI: 10.3389/fmicb.2022.900681] [Reference Citation Analysis]
5 Wombwell E, Bransteitter B, Gillen LR. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic. Mycoses 2021;64:1521-6. [PMID: 34585799 DOI: 10.1111/myc.13375] [Reference Citation Analysis]